Joint FDA, NCI Program Aims to Streamline Cancer Drug Development

2003 ◽  
Keyword(s):  
Drug Development ◽  
Cancer Drug

Diverse thiophenes as scaffolds in anti-cancer drug development: A concise review

2020 ◽  
Vol 20 ◽  
Author(s):  
Neha V. Bhilare ◽  
Pratibha B. Auti ◽  
Vinayak S. Marulkar ◽  
Vilas J. Pise
Keyword(s):  
Drug Development ◽  
Anticancer Agents ◽  
Heterocyclic Ring ◽  
Biologically Active Compounds ◽  
Biologically Active ◽  
Cancer Drug ◽  
Active Compounds ◽  
Natural Origin ◽  
Concise Review ◽  
Anti Cancer

: Thiophenes are one among the abundantly found heterocyclic ring systems in many biologically active compounds. Moreover various substituted thiophenes exert numerous pharmacological actions on account of their isosteric resemblance with compounds of natural origin thus rendering them with diverse actions like antibacterial, antifungal, antiviral, anti-inflammatory, analgesic, antiallergic, hypotensives etc.. In this review we specifically explore the chemotherapeutic potential of variety of structures consisting of thiophene scaffolds as prospective anticancer agents.

Prevascularized, Co-Culture Model for Breast Cancer Drug Development

2012 ◽  
Author(s):  
Lauren Marshall ◽  
Isabel Löwstedt ◽  
Paul Gatenholm ◽  
Joel Berry
Keyword(s):  
Breast Cancer ◽  
Drug Development ◽  
Three Dimensional ◽  
Human Tumor ◽  
3D Models ◽  
Cancer Drug ◽  
Cancer Therapies ◽  
Anti Cancer

The objective of this study was to create 3D engineered tissue models to accelerate identification of safe and efficacious breast cancer drug therapies. It is expected that this platform will dramatically reduce the time and costs associated with development and regulatory approval of anti-cancer therapies, currently a multi-billion dollar endeavor [1]. Existing two-dimensional (2D) in vitro and in vivo animal studies required for identification of effective cancer therapies account for much of the high costs of anti-cancer medications and health insurance premiums borne by patients, many of whom cannot afford it. An emerging paradigm in pharmaceutical drug development is the use of three-dimensional (3D) cell/biomaterial models that will accurately screen novel therapeutic compounds, repurpose existing compounds and terminate ineffective ones. In particular, identification of effective chemotherapies for breast cancer are anticipated to occur more quickly in 3D in vitro models than 2D in vitro environments and in vivo animal models, neither of which accurately mimic natural human tumor environments [2]. Moreover, these 3D models can be multi-cellular and designed with extracellular matrix (ECM) function and mechanical properties similar to that of natural in vivo cancer environments [3].

Modeling human carcinomas: Physiologically relevant 3D models to improve anti-cancer drug development

2014 ◽  
Vol 79-80 ◽  
pp. 50-67 ◽  
Author(s):  
Christine Unger ◽  
Nina Kramer ◽  
Angelika Walzl ◽  
Martin Scherzer ◽  
Markus Hengstschläger ◽  
...  
Keyword(s):  
Drug Development ◽  
3D Models ◽  
Cancer Drug ◽  
Anti Cancer ◽  
Human Carcinomas

scholarly journals Prospect of reprogramming replication licensing for cancer drug development

2021 ◽  
Vol 136 ◽  
pp. 111190 ◽  
Author(s):  
Isaac Kyei Barffour ◽  
Desmond Omane Acheampong
Keyword(s):  
Drug Development ◽  
Cancer Drug

Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development

Life Sciences ◽  
2021 ◽  
Vol 285 ◽  
pp. 119993
Author(s):  
Amal M. Shoeib ◽  
Azure L. Yarbrough ◽  
Benjamin M. Ford ◽  
Lirit N. Franks ◽  
Alicja Urbaniak ◽  
...  
Keyword(s):  
Drug Development ◽  
Ewing Sarcoma ◽  
Cannabinoid Receptors ◽  
Cancer Drug ◽  
Anti Cancer

Essential Drug Properties and Stages in Anti-Cancer Drug Development

2020 ◽  
pp. 29-41
Author(s):  
Andrew G. Mtewa ◽  
Duncan Sesaazi ◽  
Amanjotannu ◽  
Serawit Deyno
Keyword(s):  
Drug Development ◽  
Cancer Drug ◽  
Essential Drug ◽  
Anti Cancer

scholarly journals A NEW CYTOTOXIC DOLABELLANE FROM THE INDONESIAN SOFT CORAL Anthelia sp.

2013 ◽  
Vol 13 (3) ◽  
pp. 216-220 ◽  
Author(s):  
Anggia Murni ◽  
Novriyandi Hanif ◽  
Junichi Tanaka
Keyword(s):  
Mass Spectrometry ◽  
Drug Development ◽  
Ethyl Acetate ◽  
Spectroscopic Data ◽  
Soft Coral ◽  
Ethyl Acetate Extract ◽  
2D Nmr ◽  
Cancer Drug ◽  
Nmr Data ◽  
Anti Cancer

One new dolabellane (1) and two known diterpenoids stolonidiol (2) and clavinflol B (3) have been isolated from the ethyl acetate extract of the Indonesian soft coral Anthelia sp. A new compound 1 exhibited a moderate cytotoxicity against NBT-T2 cells at 10 µg/mL, while known compounds 2 and 3 showed cytotoxicity at 1 and 0.5 µg/mL, respectively. Structure of the new compound 1 was elucidated by interpretation of NMR spectroscopic data (1D and 2D NMR data) and mass spectrometry (ESIMS data) as well as comparison with those of related ones. This finding should be useful for anti cancer drug development of the promising dolabellane-types compound.

Expression genomics and cancer drug development

2004 ◽  
Vol 62 (4) ◽  
pp. 295-302 ◽  
Author(s):  
Edison T. Liu
Keyword(s):  
Drug Development ◽  
Cancer Drug
Sign in / Sign up

Export Citation Format

Share Document